The response rate to Amtagvi was higher in patients who had received two or fewer therapies than in those with more heavily ...

Results from a retrospective study found that Amtagvi (lifileucel) achieved a 48.8% objective response rate in patients with ...

Iovance Biotherapeutics’ Amtagvi study data shows 49 per cent response rate for commercialisation: San Carlos, California Thursday, July 17, 2025, 12:00 Hrs [IST] Iovance Biothe ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

A real-world study showed a 49% response rate with Amtagvi in patients with advanced melanoma, supporting earlier use after immunotherapy.

(NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today ...

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the 10 best healthcare penny stocks to buy according to analysts. Goldman Sachs reiterated its “Buy” rating on Iovance’s stock on June 3. The firm ...

Amtagvi is intended to treat patients who have advanced melanoma and who have already been treated with a common immunotherapy drug called pembrolizumab.

Amtagvi and Proleukin® demand remains strong and continues to increase as authorized treatment centers (ATCs) adopt Amtagvi and community referral networks are mobilized to drive patients to ATCs.

Amtagvi is also being evaluated in separate mid-stage studies for cervical and endometrial cancer indications. IOVA’s Zacks Rank Iovance currently has a Zacks Rank #4 (Sell).

Unfortunately, Amtagvi is not an easy-to-swallow small molecule or even an injectible protein. It's a collection of autologous immune cells called tumor-infiltrating lymphocytes, or TILs.

Significant Demand for Amtagvi™ (Lifileucel) Continues with $58.6M in Total 3Q24 Product Revenue Reaffirming Guidance of $160-$165M for FY24 and $450-$475M for FY25 of Total Product Revenue ...